COMPASS Pathways (CMPS)
(Delayed Data from NSDQ)
$6.21 USD
+0.32 (5.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $6.20 -0.01 (-0.16%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.21 USD
+0.32 (5.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $6.20 -0.01 (-0.16%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
COMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat
by Zacks Equity Research
Investors are likely concerned about Pediatrix's (MD) lower enrollment in commercial insurance programs, escalating practice salaries and benefits and net borrowings.
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and COMPASS Pathways PLC Sponsored ADR (CMPS) have performed compared to their sector so far this year.
All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy
by Zacks Equity Research
COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?
by Zacks Equity Research
Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
by Andrew Rocco
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
COMPASS Pathways PLC Sponsored ADR (CMPS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
COMPASS Pathways PLC Sponsored ADR (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 289% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 288.6% upside potential for COMPASS Pathways PLC Sponsored ADR (CMPS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 781% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 781.4% in COMPASS Pathways PLC Sponsored ADR (CMPS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health.
3 Psychedelic Stocks to Play the Shroom Boom
by Sejuti Banerjea
Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.
Is the Options Market Predicting a Spike in COMPASS Pathways (CMPS) Stock?
by Zacks Equity Research
Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in COMPASS Pathways (CMPS) Stock?
by Zacks Equity Research
Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.
Zacks Industry Outlook Highlights: Avantor, Eurofins Scientific, GoodRx Holdings, Apollo Medical and COMPASS Pathways
by Zacks Equity Research
Zacks Industry Outlook Highlights: Avantor, Eurofins Scientific, GoodRx Holdings, Apollo Medical and COMPASS Pathways
5 Top Medical Services Stocks to Beat COVID-Led Industry Challenges
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Services industry. AVTR, ERFSF, GDRX, AMEH and CMPS are poised to gain.